Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1161320 | 0.78 | EPHX2 (0.45) | EPHX2CYP2D6CYP2C19MCL1NR4A2 | |
| SCHEMBL20539643 | 0.77 | CA1 (0.38) | CYP2D6CYP2C19CA2 | |
| SCHEMBL15934045 | 0.76 | CA2 (0.46) | EPHX2CA2 | |
| SCHEMBL18778812 | 0.75 | LDHA (0.42) | EPHX2CA2NR4A2CXCL8 | |
| SCHEMBL13901443 | 0.75 | EPHX2 (0.34) | EPHX2CXCL8 | |
| SCHEMBL18160817 | 0.74 | EPHX2 (0.38) | EPHX2CA2CXCL8PTGES | |
| SCHEMBL22949988 | 0.73 | TERT (0.39) | EPHX2CA2MCL1CXCL8PTGES | |
| SCHEMBL16003170 | 0.72 | CA12 (0.46) | CA2 | |
| SCHEMBL13269961 | 0.72 | L3MBTL1 (0.35) | CYP2D6CYP2C19CA2 | |
| SCHEMBL695182 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| EP-3612525-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018195321-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | EPHX2 3909/4885CYP2D6 1713/4885CYP2C19 3024/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | EPHX2 3909/4885CYP2D6 1713/4885CYP2C19 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.